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1. Introduction
The chapter briefly covers the history of protein and peptide neurotoxins in research on
nicotinic acetylcholine receptors (nAChR). It all started with a great help of α-bungarotoxin
and other similar α-neurotoxins from snake venoms in isolation from the Torpedo ray electric
organ of the muscle-type nAChR as a first individual membrane receptor. The next contribu‐
tion of α-neurotoxins was the discovery with their aid of the first neuronal nAChR in the brain
now known as homooligomeric α7 nAChR. An overview of various α-neurotoxins (so-called
three-finger toxins) is presented below showing the structural differences between them, as
well as the benefits of their current application for identification and quantification of different
nAChR subtypes at normal state and at various pathologies such as Alzheimer’s and Parkin‐
son’s diseases, psychiatric diseases and nicotine addiction. A special emphasis is placed on the
work at our institute, starting with the first detection of nAChRs as targets for the so-called
weak or “non-conventional” neurotoxins. Recently, in proteomic studies of snake venoms,
novel structural types have been discovered, such as covalently connected dimeric α-cobra‐
toxin or, on the contrary - azemiopsin, the first peptide from venoms which does not contain
disulfide bonds but still blocks selectively the muscle-type nAChR.
A generous source for sophisticated tools in research on nAChRs is combinatorial peptide
libraries from the venoms of Conus marine snails. In particular, they contain α-conotoxins
which not only distinguish muscle nAChRs from neuronal ones, but some of them block
specifically distinct neuronal nAChR subtypes. At present, combinations of snake and snail
toxins are widely used in fundamental research and in pharmacological studies.
The chapter briefly summarizes information on the spatial organization and subunit compo‐
sition of different nAChR subtypes, but considers in more detail important contributions of
peptide and protein neurotoxins into elucidation of the topography of the nAChR binding
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sites. The information mainly came from the X-ray structures of their complexes with the
acetylcholine-binding protein (AChBP), an excellent structural model of the ligand-binding
domain of nAChRs. These complexes are considered as initial blocks for design of novel drugs.
2. Muscle-type, neuronal and “non-neuronal” nAChRs — Brief overview
Before considering in detail protein and peptide neurotoxins on which the Chapter is mostly
focused, it is reasonable to give very shortly the information about various types of nAChR
which will make easier later discussions of the specificity of one or another toxin to a particular
nAChR subtype.
As mentioned in the Introduction, α-bungarotoxin made possible identification and isolation
in a pure form of the nAChR from the Torpedo ray electric organ. Later it was found that this
receptor is composed of 5 subunits arranged around the central axis along which an ion channel
should be arranged (Figure 1, A). The subunits in the order of their increasing molecular masses
(estimated from the SDS-gel electrophoresis) have been named α, β, γ and δ. The molecular
mass of the receptor complex is around 250 kD and it should contain two α subunits and by
one of the “non- α” subunits. When nucleotide sequences of the Torpedo nAChR subunits and
of those from mammalian muscles were established it became clear that those receptors are
highly homologous. In fact, the mammalian embryonic nAChR has the same subunit stoichi‐
ometry (2α, β, γ and δ), but in the mature form it has an ε subunit instead of γ. Although the
relevant information at present is available in numerous biochemistry books and reviews [1-4],
it should be mentioned here that nAChRs are ligand-gated ion channels: binding of a ligand
(acetylcholine, nicotine or other specific agonists) will result in the channel opening and
passing sodium or calcium ions will activate a variety of signaling cascades. On the other hand,
binding at the same sites of competitive antagonists such as α-bungarotoxin will prevent both
binding of agonists and subsequent channel opening; some so-called non-competitive
antagonists, like phencyclidine, bind directly to the channel moiety but they are not discussed
here.
Earlier it was thought that the ligand-binding sites of nAChRs lie within the α-subunits, hence
there should be two binding sites on the muscle-type nAChRs. To-day we know that, indeed,
the main contributions to binding of agonists or competitive antagonists are donated by the
α-subunits. Moreover, even isolated α-subunit and its fragment in the amino-acid region
170-200 can bind α-bungarotoxin, although with lower affinity than the whole-size receptors
[5,6]. However, now it is well established that the binding sites are situated at the interfaces of
the α-subunits with their neighbors, and it is the variability of functional groups brought to
the binding sites by less conservative “non-alpha” subunits which underlies the differences in
specificity between individual nAChR subtypes [4].
What are the types and subtypes of nicotinic acetylcholine receptors? As mentioned above,
binding of radioactive α-bungarotoxin to brain membranes finally brought to life the nAChR
presently known as homopentameric α7 nAChR that is composed of five identical α7-subunits.
Thus, we have an example of homooligomeric receptor belonging to the family of neuronal
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nAChRs. Neuronal heteromeric nAChRs are composed of two types of subunits: α and β. At
present there are 9 types of neuronal α-subunits (α2-α10) and three types of β subunits (β2-
β4); α and β subunits in the muscle-type receptors presumed to be α1 and β1 ones. The
characteristic feature of α-subunit is a vicinal disulfide between two neighboring Cys residues
in the binding site (Cys192-Cys193 in the amino-acid sequence of the Torpedo α-subunit) which
is not present in β or other “non-α” subunits. In recent years it became clear that diverse
nAChRs are very much widespread and play different functional roles also outside the neuro-
muscular junctions or central nervous system. In fact, neuronal nAChR subunits were found
on the immune system cells, skin, lung tissue and other. The respective receptors got the name
of “non-neuronal” nAChRs thus making a third group of nicotinic acetylcholine receptors (see
reviews [7,8]).
Figure 1. Spatial organization of nAChRs. А – Schematic presentation of Torpedo nAChR, consisting of 5 subunits with
the ion channel along the central axis. Two binding sites of agonists (acetylcholine and others) and competitive antag‐
onist (α-neurotoxins from snakes, α-conotoxins from Conus mollusks and others) are located at the interfaces of the
α1/γ and α1/δ-subunits and marked with asterisks. В – Spatial organization of Torpedo marmorata nAChR derived
from its cryo-electron microscopy structure. Subunits α1, β1, γ and δ are colored in red, green, cyanic and blue, respec‐
tively. Three main domains of the receptor – extracellular (ECD), transmembrane (TMD), consisting of 4 α-helical frag‐
ments (M1-M4), and intracellular (ICD) are shown. C – Schematic presentation of two representatives of neuronal
nAChRs – homooligomeric and heterooligomeric ones. The probable binding sites of agonists and competitive antag‐
onist are marked with black circles.
Structurally, the Torpedo nAChR is a prototype for all members of the nAChR family. First of
all, it is a pentamer (composed of 5 subunits) as follows from the cryo-electron microscopy
structure of the Torpedo marmorata receptor (see Figure 1, B). There are no structural data of
this sort for any other nAChR, but their pentameric composition was presumed from computer
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modeling and from some indirect data like electrophysiology analysis. At present there are no
doubts that all nAChRs are indeed either pentameric homooligomers (made exclusively of 5
α-type subunits, like α7 nAChR, α9 nAChR or α9/α10 nAChR) or pentameric heterooligomers
(composed of α and other subunits) (Figure 1, C) – for example, one of the best presented in
the brain is α4β2 nAChR [9]. As already mentioned, all nAChRs should be built similarly to
Torpedo nAChR: namely, four transmembrane fragments M1-M4 in each subunit, the most
inner ones M2 fragments lining the channel, the N-terminal extracellular fragments of each
subunit together forming the ligand-binding domain excellently imitated by the X-ray
structure of the acetylcholine-binding protein (AChBP) (see below). The long intracellular
loops between transmembrane fragments M3 and M4 of each subunit together form the
cytoplasmic (intracellular) domain.
The first and the most direct structural evidence for a common three-dimensional organization
of all nAChRs came from the crystal structure of AChBP [10]. Today even more convincing
are the recently solved high-resolution X-ray structures of the whole-size prokaryotic mem‐
brane proteins belonging to the same superfamily of Cys-loop ligand-gated ion channels as
nAChRs [11-13]. These proteins, each composed of 5 identical subunits, do not have large
cytoplasmic domains (which apparently made their crystallization much more simple than of
nAChRs or other mammalian Cys-loop receptors), but in the transmembrane and ligand-
binding domains they are surprisingly similar to Torpedo nAChR. Moreover, the same type of
structure was found for a Cys-loop receptor from Caenorhabditis elegans [14]. Now, after having
these major facts about nicotinic acetylcholine receptors, we can open our toolbox and have a
closer look on protein and peptide neurotoxins.
3. Snake venom neurotoxins utilized in research on nAChRs — Primary
and three-dimensional structure
The word “toolbox“ in the chapter title in the first place is related to the snake venom proteins,
at least historically. It was the component of Bungarus multicinctus venom which was found to
block very efficiently the muscle-type nAChRs and could be considered as a good marker of
those receptors. The history of the discovery of such a tool, namely protein neurotoxin α-
bungarotoxin, is presented in a recent review [15]. There Prof. Chang shares his memories
about this discovery (exactly 50 years ago!) which played such a crucial role in understanding
the structure and function of both snake neurotoxins and of one of their targets, namely
nAChRs. Soon after the discovery of α-bungarotoxin, similar proteins were found in other
snakes, in particular in cobra venoms and the whole family got the name of α-neurotoxins (see
reviews [15-17]).
3.1. α-Neurotoxins
There are two structural types of α-neurotoxins: short-chain α-neurotoxins (60-62 amino acid
residues, 4 disulfide bridges) and long-chain ones (66-75 amino acid residues, 5 disulfide
bonds). The first X-ray structures have been determined for the short-chain α-neurotoxins,
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namely for erabutoxins a and b [18,19] (see Figure 2, A). The molecule has three loops, with a
predominant β-structure, fixed in the space by 4 disulfide bridges forming a sort of a knot.
This folding gave the name of “three-finger proteins” to α-neurotoxins. Later spatial structures
have been determined both by NMR and X-ray crystallography for different short- and long-
chain α-neurotoxins, including α-bungarotoxin [20,21]. Long-chain α-neurotoxins have the
same three -finger folding as the short ones, but contain a longer C-terminal tail and an
additional 5th disulfide in the central loop II (Figure 2, B). In the structures of some long-chain
α-neurotoxins (α-bungarotoxin, α-cobratoxin [22] or neurotoxin I from Naja oxiana [23]) a short
α-helical fragment was found at the tip of the loop II (see Figure 2, B).
Figure 2. Spatial structures of snake ‘three-finger’ toxins interacting with nAChRs. The ‘fingers’ are marked with Ro‐
man numbers; N-termini are labeled as well. A - erabutoxin a (PDB ID: 5EBX). B – α-bungarotoxin (1KFH); the 5th disul‐
fide bridge in loop II is colored in magenta (contrary to all other disulfides in orange) and α-helix at tip of this loop is
colored intentionally in contrast green. C – κ-bungarotoxin (1KBA); 5th disulfide bridges in loops II are colored in red. D
– haditoxin (3HH7). E – dimeric α-cobratoxin (4AEA), where disulfide bridges between Cys3 from one monomer and
Cys20 from the second monomer stabilize the dimeric molecule; two monomers are shown in blue and magenta, re‐
spectively. F - irditoxin (2H7Z); ‘non-conventional’ disulfides in loops I are colored in red and disulfide bond between
the monomers is shown in blue. G - candoxin (1JGK); disulfide in loop I is shown in red.
One of the characteristic features of α-neurotoxins is the stability of their three-dimensional
structure fixed by 4 or 5 disulfide bridges. This conclusion is supported by high similarity of
spatial structures determined by NMR at different conditions (varying pH and temperatures)
and by X-ray crystallography. This may be one of the crucial factors explaining high efficiency
of α-neurotoxin interactions with their targets, nicotinic acetylcholine receptors. As will be
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shown later, α-neurotoxins essentially preserve their conformation in complexes with the
AChBP [24], with the ligand-binding domain of individual α1 subunit of nAChR [25] and with
the chimera of AChBP and α7 nAChR extracellular domain [26].
3.2. Dimeric three-finger neurotoxins
First of all, we should mention here κ-bungarotoxins and several homologous neurotoxins
which are dimers, but do not have covalent intermolecular bonds between monomers [27].
Each monomer is very similar to a typical long-chain α-neurotoxin: the same additional 5th
disulfide at the tip of the central loop II, but a slightly shorter C-terminal tail (total number of
amino acid residues 66 but not 75 as in α-bungarotoxin) (see Figure 2, C). The molecular targets
of κ-bungarotoxins are neuronal nAChRs, but contrary to α-neurotoxins they have high
affinity to neuronal α3β2 nAChR [28]. Interestingly, it was established about 20 years ago that
there is one common property of α-neurotoxins and κ-neurotoxins, namely the additional
disulfide in the loop II is essential for recognition of neuronal nAChRs. It was found that
selective reduction of that disulfide and subsequent alkylation or removal of the respective
cysteines in both types of toxins abolished their high affinity binding to α7 and α3β2 nAChRs,
respectively (without decreasing the affinity of long-chain α-neurotoxins to muscle-type
nAChRs [29,30]). On the other hand, introduction of additional disulfide into the central loop
of short-chain α-neurotoxins considerably increased their affinity for α7 nAChR [31,32].
It is not yet absolutely clear why κ-bungarotoxins have preference for heteromeric nAChRs.
There was a hypothesis that an important role in selectivity of κ-bungarotoxins towards α3β2
nAChRs belongs to the residue Lys26 [24]. However, its introduction to α-neurotoxin having
a high affinity for α7 nAChRs only decreased considerably binding to this receptor but did not
bring any affinity for α3β2 nAChRs [32]. Apparently, dimerization as such is important to force
a protein, composed of two classical α-neurotoxins, to recognize a heteromeric neuronal
nAChRs as can be seen on the example of other recently discovered dimeric neurotoxins.
One toxin, haditoxin from the King cobra venom [33] looks very similar to κ-bungarotoxin.
Haditoxin is a non-covalent dimer composed of two short-chain α-neurotoxins, rather than of
long-chain ones, and the monomers adopt a topological arrangement (Figure 2, D) reminiscent
of that observed earlier for monomers in κ-bungarotoxin. Haditoxin can block not only muscle-
type nAChRs, as typically observed for short-chain α-neurotoxins, but surprisingly it also
blocks homooligomeric α7 and heterooligomeric α3β2 nAChRs. This finding appears to be in
contradiction with the earlier found necessity of the additional disulfide in the central loop for
recognition of neuronal nAChRs. However, it should be kept in mind that blocking of neuronal
nAChRs by haditoxin was observed only at very high toxin concentrations [33]. It should be
also mentioned that, strictly speaking, haditoxin cannot be assigned to classical short-chain
α-neurotoxins because its homology to erabutoxin is only 50%, whereas it is 75-80% with the
muscarinic toxin-like proteins (MTLP) having different targets [34].
Novel types of dimeric α-neurotoxins were recently discovered: contrary to κ-bungarotoxin
or haditoxin, these are covalently bound where two molecules of α-cobratoxin are connected
by two intermolecular disulfide bonds [35]. Before describing a biological activity of this new
tool, it should be mentioned that such intermolecular disulfide is the first case of this post-
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translational modification found for the whole huge family of three-finger toxins. Dimeric α-
cobratoxin retained, although at a lower level, the capacity to block α7 and muscle-type
nAChRs and in addition acquired the ability to block α3β2 nAChR - again, with lower potency
than did κ-bungarotoxin [35]. Interestingly, selective reduction of the disulfides in the loop II
of dimeric α-cobratoxin abolished its activity against α7 nAChR. It could be expected in view
of earlier described similar modification of α-cobratoxin itself, but this chemical modification
even increased the affinity for α3β2 nAChR [36]. Since dimeric α-cobratoxin is present in the
Naja kaouthia cobra venom only in minute amounts (0.01% in crude venom, as compared to
10% for α-cobratoxin itself or to 0.1% for κ-bungarotoxin), unequivocal localization of inter‐
molecular disulfides by chemical means could not be done. Fortunately, dimeric α-cobratoxin
has been recently crystallized (Figure 2, E) and the high-resolution X-ray structure revealed
the disposition of the intermolecular disulfide bridges: the disulfide Cys3-Cys20 or Cys3’-
Cys20’ in each monomer is not formed, but Cys3 of one monomer finds Cys20’ of another
monomer, while Cys3’ of the latter makes a disulfide with Cys20 of the former [36].
As will be shown later, the main contribution to binding of α-neurotoxins both to nAChRs and
to their models comes from the tip of the central loop II of α-neurotoxins. In dimeric α-
cobratoxin the two tips are in close proximity and computer modeling showed impossibility
of docking such a structure to AChBP, suggesting that some conformational changes should
occur in the dimeric α-cobratoxin to ensure its binding observed in radioligand and electro‐
physiology experiments [36].
The discovery of dimeric α-cobratoxin was followed by finding another three-fingered toxin
where monomers are connected by a disulfide bridge [37]. It was irditoxin isolated from
Colubrid snake Boiga irregularis. In contrast to dimeric α-cobratoxin present in venom in minor
amounts, irditoxin is a main component of boiga venom. Again, strictly speaking, irditoxin is
neither a short- nor a long-chain α-neurotoxin: the monomers forming this toxin belong to non-
conventional toxin type (see below) and each monomer contains an extra cysteine residue
forming one disulfide bridge between two monomers (or protomers). None of these cysteines
is present in classical α-neurotoxins. In the first protomer, the additional cysteine is located in
loop I whereas in the second protomer it is in loop II. The three-dimensional structure of
irditoxin [37] (see Figure 2, F) shows that the central loops II of the two protomers are oriented
in a similar way as the central loops of dimeric α-cobratoxin (Figure 2, E).
3.3. Weak (non-conventional) three-fingered neurotoxins
A characteristic feature of this group of three-fingered toxins is the presence of additional
disulfide bridge not in the central loop II, as in long-chain α-neurotoxins or in κ-bungarotoxins,
but in the N- terminal loop I. Some representatives of this group were known long ago, but
many of them did not have a strong toxicity (that is why their name was “weak toxins”) and
their targets were unknown. At present this group of toxins, consisting of 62-68 amino acid
residues, is quite well investigated and has a more general name “non-conventional neuro‐
toxins” [38]. The toxicities for the most of group members are very low (5-80 mg/kg) in contrast
to classical α-neurotoxin with toxicities in the range from 0.04 to 0.3 mg/kg. However, some
very potent toxins (like γ-bungarotoxin with LD50 of 0.15 mg/kg) are also included in the
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group of non-conventional toxins. Since, as mentioned above, molecular targets of weak (non-
conventional) toxins for a long time were unknown, an important step in this field was the
work [39] where was discovered that weak toxin (WTX) from Naja kaouthia cobra venom
interacted with micromolar affinity with the α7 and muscle-type nAChRs, the binding being
practically irreversible. Later it was found [40] that candoxin (Figure 2, G), another non-
conventional toxin, interacted both with α7 and muscle-type nAChR with high affinity. An
interesting feature of candoxin is that its attachment to the muscle-type receptor was easily
reversible. Even more impressing species specificity was reported for denmotoxin, a non-
conventional toxin isolated from Colubrid snake Boiga dendrophila: it was able to interact
irreversibly and with high affinity with chick muscle nAChR, but only with low affinity with
mouse receptors [41].
3.4. Three-finger snake neurotoxins having other targets than nicotinic acetylcholine
receptors
Before considering in detail the mechanisms of interactions between α-neurotoxins and
nAChRs and describing their earlier and current roles of tools, it is appropriate to say a few
words about the whole family of three-finger proteins from snake venoms (see reviews [16,17]).
They all have the same “three-finger” fold but are decorated with quite different functionally
active amino-acid residue and, as a result, attack distinct targets. For example, in the preceding
paragraph we considered WTX from Naja kaouthia venom which blocked nicotinic acetylcho‐
line receptors. Its very low toxicity allowed testing of its behavioural activity on rats which
suggested action on muscarinic acetylcholine receptors [42]. Indeed, subsequent radioligand
analyses revealed the WTX interaction with the different subtypes of muscarinic acetylcholine
receptors [43]. It should be noted here that we have a dualism of action for this group of the
three-finger proteins from snake venom: namely, blocking of one acetylcholine receptor (the
nicotinic one) belonging to the family of ligand-gated ion channels and another acetylcholine
receptor, the muscarinic one which is a member of the superfamily of G-protein-coupled
receptors (GPCR).
Much more strong effects on muscarinic acetylcholine receptors exert so-called muscarinic
neurotoxins isolated from the green mamba Dendroaspis angusticeps [44-46]. Structurally these
proteins are of the same type as short-chain α-neurotoxins. Interestingly, they can distinguish
different subtypes (M1-M7) of muscarinic acetylcholine receptors and on some of them exert
not the inhibitory, but the potentiating effects. There is not yet much information about how
muscarinic toxins recognize their targets. A large series of mutations was performed both on
the muscarinic toxin MT7 and on the M1 muscarinic receptor and the results of this pair-wise
mutagenesis, analyzed by computer modelling, indicated that all three loops I-III should be
involved in the interaction and the main binding site for this allosteric modulator is located in
the extracellular loops of the receptor [46].
There are also several three-finger proteins from snake venoms (calciceptin, FS2) blocking
Ca2+ channels [47,48]. We should also mention here fasciculin, a three-finger protein with 4
disulfides, targeting the acetylcholinesterase. Interestingly, the X-ray structures of fasciculin
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in complex with acetylcholinesterases were the first examples presenting a three-finger toxin
bound to its biological target [49,50].
One of the most well-represented groups in the snake venoms are so-called cytotoxins (some
of them were earlier called cardiotoxins) which apparently do not have a single well-defined
target but disrupt the cell membranes thus inducing a multitude of effects (see reviews [51,52]).
As a result of proteomic studies new three-finger proteins are being found in the snake venoms,
and one of the minor components in the Naja kaouthia cobra venom was identified as a
glycosylated cytotoxin I [53]. This post-translational modification, for the first time discovered
for the family of three-finger toxins, considerably decreased the cytotoxicity of this protein,
whereas enzymatic deglycosylation restored it to the level of cytotoxin I activity [53]. Another
really a minor component of that venom (less than 0.01% in the crude venom) was a dimer of
cytotoxin and α-cobratoxin connected by two intermolecular disulfide bridges which revealed
a weak activity against neuronal nicotinic acetylcholine receptors [35].
We also would like to mention here the recent discovery of three-finger neurotoxins which
interact with another group of GPCR, namely with the adrenoreceptors [54,55]. These toxins
are most similar to muscarinic toxins and were also isolated from the eastern green mamba
Dendroaspis angusticeps. One such toxin (ρ-Da1a) has a very high affinity (0.35 nM) for the α1
adrenoreceptor, while another one (ρ-Da1b) has a lower affinity but is more selective towards
α2 types [55]. Interestingly, these toxins are considered as possible drugs against prostate
hypertrophy.
Although it is not the topic of the present review, it is appropriate to mention here that there
are three-finger proteins in nervous and immune system of mammals and insects belonging
to the Ly6 family and some of them bind to nicotinic acetylcholine receptors and regulate their
functioning in vivo (see [56-59] and recent publications from our institute [60-63]).
3.5. Peptides from snake venoms acting on nicotinic acetylcholine receptors
Such peptides are not as numerous as α-neurotoxins or non-conventional toxins targeting
different subtypes of nAChR. Until recently the only group was that of waglerins isolated from
the venom of South Asian snake Tropidolaemus wagleri which consist of 22-24 amino acids and
contain one disulfide bridge [64,65]. These toxins bind with high affinity to muscle-type
nAChR [66]. Interestingly, waglerins can distinguish embryonic (α12β1 γδ) and “mature”
(α12β1εδ) muscle-type nAChR: waglerin-1 efficiently blocks the ε-containing form, but not the
γ-form of this receptor [67]. While snake venom α-neurotoxins bind with practically equal
efficiency to the two binding sites (formed by two α-subunits with their non-α neighbors) in
the muscle-type nAChRs, waglerin-1 binds 2100-fold more tightly to the α-ε than to the α-δ
binding site of the mouse nAChR [68]. Several amino acid residues in the nAChR subunits
participating in waglerin binding were identified by site directed mutagenesis [69], namely
Asp59 and Asp173 were shown to be important for waglerin binding at both sites. On the other
hand, the disulfide in waglerin was found to be essential for its activity, as well as several
residues in its N-terminal part of the amino acid sequence [70].
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A new peptide was recently found in the snake venom possessing a capacity to block muscle-
type nAChR [71]. It is azemiopsin, isolated from the Azemiops feae viper venom, which consists
of 21 amino acid residues. By the chain length azemiopsin is similar to waglerins and,
moreover, shares with them a homologous C-terminal fragment. However, it possesses a
unique structural feature: contrary to all earlier known proteins and peptides from the venoms
of snakes or poisonous Conus mollusks (see below), whose structure is fixed by one or several
S–S-bonds, azemiopsin contains no disulfides. It dose-dependently blocked acetylcholine-
induced currents in Xenopus oocytes heterologously expressing human muscle nAChR, and
was more potent against the adult (α12β1εδ) than the fetal (α12β1γδ) form. Ala-scanning and
analysis of competition with α-bungarotoxin for binding to Torpedo nAChR resulted in
identification of the azemiopsin residues essential for its activity which in general were found
to be different from those responsible for the waglerin activity [71].
4. α-Conotoxins, peptides from poisonous marine snails Conus, acting on
nicotinic acetylcholine receptors
Historically, snake venom α-neurotoxins were the first extremely important tools which made
possible “digging out” in a purified form the first representative of the nAChR family, namely
the muscle-type receptor from the Torpedo ray electric organ. Then, in the early 80s, the peptide
toxins were discovered in the marine mollusk Conus geographus venom which caused postsy‐
naptic inhibition at the neuromuscular junction in frog and got the name of conotoxins [72].
The following studies brought to life a tremendous number of so-called conotoxins or cono‐
peptides from different species of Conus snails. The number of Conus species living in different
seas and oceans is about 1000 and the available data show that the venom of each species
should contain in excess of 1000 conopeptides. Thus, Conus mollusks provide researchers with
huge combinatorial libraries of peptides. The main task of slowly moving Conus mollusks is
to immobilize their preys (small fishes, worms etc.), that is why their venoms contain a variety
of peptides paralyzing the nervous systems of their targets. Evolutionary each Conus species
is adjusted to a particular area and a distinct food source, hence the individuality of each
venom. There are several types of conotoxins differing in their targets: α-conotoxins block
nAChRs, μ-conotoxins are acting on Na+-channels, κ-conotoxins interact with K+-channels, ω-
conotoxins block specifically certain Ca2+-channels and one of such ω-conotoxins became a
very potent analgesic (trade name Ziconotide or Prialt; see more about these and many other
conotoxins and conopeptides in recent reviews [73-75]). The number of discovered conotoxins
is rapidly increasing because nowadays they appear not so much due to isolation from Conus
venoms (usually available only in minute amounts) but due to deciphering mRNAs obtained
from the venom glands.
Since this chapter is devoted to neurotoxic proteins and peptides interacting with nicotinic
acetylcholine receptors, below we will consider only those conotoxins which target these
receptors. The major group is α-conotoxins, competitive antagonists of nAChRs. They have
12-19 amino-acid residues, as a rule amidated C-terminus and two disulfide bonds between
Cys residues C1–C3 and C2–C4 (see Table). There are also several other groups of conotoxins
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acting on nAChRs (ψ-, αA-, αAS-, αC-, αS- and αD), but they are not numerous, are not as
widely used as α-conotoxins and will not be considered here.
Toxin Conus species Amino acid sequence 1 Selectivity
3/5 α-conotoxins
GI C. geographus ECCNPACGRHYSC* α1β1γ/εδ
MI C. magus GRCCHPACGKNYSC* α1β1γ/εδ
SIA C. striatus YCCHPACGKNFDC* α1β1γ/εδ
4/3 α- conotoxins
ImI C. imperialis GCCSDPRCAWRC* α7, α9α10; α3β2; α3β4
RgIA C. regius GCCSDPRCRYRCR α9α10
4/4 α- conotoxins
BuIA C. bullatus GCCSTPPCAVLYC* α3(α6)β2, α3(α6)β4
4/6 α- conotoxins
AuIB C. aulicus GCCSYPPCFATNPDC* α3β4
4/7 α- conotoxins
PnIA C. pennaceus GCCSLPPCAANNPDYC* α3β2
PnIВ C. pennaceus GCCSLPPCALSNPDYC* α7; α3β4
MII C. magus GCCSNPVCHLEHSNLC* α3β2(β3); α6-containing
Vc1.1 C. victoriae GCCSDPRCNYDHPEIC* α9α10; α3β4, α3(α5)β2
TxIA C. textile GCCSRPPCIANNPDLC* α3β2
ArIB C. arenatus DECCSNPACRVNNPHVCRRR α7, α6α3β2β3, α3β2
1 Scheme of disulfide closing for naturally-occurring α-conotoxins –
* indicates an amidated C-terminus; the names of α-conotoxins typed in italics mean that their structures were
identified in cDNA libraries.
Table 1. Most studied members of naturally-occurring α-conotoxins.
α-Conotoxins are structurally subdivided into subgroups depending on the number of amino
acid residues between the C2–C3 and C3–C4 cysteines (see Table) forming the first and second
loops, respectively. This structural feature affects the α-conotoxin specificity to particular
nAChR subtypes. All at present known 3/5 α-conotoxins are potent blockers of muscle type
nAChRs (and conventionally can be called ‘muscle’ α-conotoxins). The members of other
subgroups (4/3, 4/4, 4/6, 4/7) act on various neuronal nAChR subtypes (and can be called
‘neuronal’ α-conotoxins). It is very rare when naturally occurring neuronal α-conotoxin blocks
specifically only one neuronal nAChR subtype, usually neuronal α-conotoxins interact with
two or more nAChR subtypes (see Table).
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Most of muscle 3/5 α-conotoxins can discriminate species-specifically two binding sites on
muscle or Torpedo nAChRs. For example, α-conotoxins MI, GI or SIA have up to10000 times
higher affinity for α1/δ- over α1/γ site in muscle nAChR [76,77]; in contrast to more effective
binding of these peptides, although not with such a great difference, to α1/γ site in Torpedo
receptor [78,79].
“Mutagenesis” studies of α-conotoxins (in fact not the mutagenesis as such, but substitutions
of amino acid residues by solid-phase peptide synthesis) gave information about those
residues which are the basis of the high affinity and selectivity to a particular receptor or
receptor subgroup. For example, the crucial role of Arg9 in α-conotoxin GI, as well as of Pro6
and Tyr12 in α-conotoxin MI for discriminating the α1/γ- and α1/δ-sites was revealed [80-82].
Interestingly, Arg9 proved important for a neuronal 4/3 α-conotoxin RgIA for its α9α10 nAChR
specificity [83]. Similar “mutagenesis” studies resulting in revelation of residues crucial for
activity were done also for many other α-conotoxins (ImI, PnIA, MII, GID, Vc1.1, AuIB) [84-89].
Like in the analysis of interactions between different nAChR types and snake venom neuro‐
toxins, when much efforts has been spent by many laboratories to establish the topography of
their binding, similar studies have been undertaken to elucidate the mechanism of nAChR
recognition by α-conotoxins. Among them were above-mentioned multiple substitutions in
the amino acid sequences of naturally occurring α-conotoxins, making their structures more
rigid, syntheses of radioactive, fluorescent and photoactivatable derivatives. Combination
with mutagenesis of the receptor subunits (pair-wise mutagenesis) gave information about
possible contact points between α-neurotoxins and nAChRs, as well as between α-conotoxins
and nAChRs. The relevant information can be found in numerous reviews (see, for example,
[90-92]), but will not be considered in detail here, because this chapter contains a special section
where crystal structures of α-neurotoxins and α-conotoxins in complexes with the relevant
biological targets will be discussed.
5. Three-dimensional structures of peptide and protein neurotoxins in
complexes with the nicotinic receptor models and fragments
It was already mentioned that the crystal structure of the acetylcholine-binding protein
(AChBP) provided an impressing jump in the structural analysis of not only nicotinic acetyl‐
choline receptors but of all other members of the Cys-loop receptor family. This water-soluble
protein was found to modulated synaptic transmission in glia of Lymnaea stagnalis fresh-water
mollusk and was purified using affinity chromatography on a column with the attached α-
bungarotoxin [93]. Sufficient amounts of AChBP were obtained by heterologous expression
and the crystal structure was determined at 2.7 Å resolution [10]. This structure clearly showed
that AChBP is an excellent structural model of N-terminal ligand-binding domains of all
nAChRs: crystal AChBP was in a pentameric state, similarly to the whole-size nAChRs. In spite
of low homology with the amino-acid sequences of extracellular domains of nAChR subunits
(not more than 25%), AChBP contains all those amino acid residues which earlier in receptor
studies were found essential for interacting with the cholinergic agonists and antagonist. The
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AChBP crystal structure revealed that such residues are all clustered in the middle of AChBP,
at the interfaces between its subunits (or protomers). At present, the X-ray structures of several
molluscan AChBPs are known (from Lymnaea stagnalis, Aplysia californica, Bulinus truncatus),
as well of their complexes with a wide variety of agonists and antagonists which gave quite a
detailed picture of the respective binding sites in these AChBPs and of their contacts with
ligands. Biochemical data and computer modeling show convincingly that these structures
shed light on the receptor binding sites per se and on the ligand disposition in the binding sites
of muscle and neuronal nAChRs. The relevant information can be found in recent original
papers [94-97] and reviews [98,99], and below we will consider in detail only the crystal
structures of complexes with protein and peptide neurotoxins.
Interestingly, the first AChBP crystal structure in complex with a competitive antagonist was
that of Lymanaea stagnalis AChBP with bound α-cobratoxin [24]. (In parentheses it may be
mentioned that later more structures were solved for the Aplysia californica AChBP complexes,
but L. stagnalis AChBP has a much higher affinity for α-neurotoxins than AChBPs from other
species). First of all, X-ray analysis revealed 5 α-cobratoxin molecules attached at the interfaces
between 5 identical subunits (or protomers) of AChBP (Figure 3, A). The major role in the
organization of the binding site is played by aromatic residues (so-called “aromatic box”) of
AChBP. Long before crystallographic studies, protein chemistry and mutagenesis revealed
that these aromatic residues were important for binding different agonists and antagonists to
diverse muscle-type and neuronal nAChRs. It was proposed that the binding sites are formed
by three fragments (A, B, C) of polypeptide chain of one subunit and by three fragments (D,
E, F) of the polypeptide chain of the other one on which these aromatic residues are located
(see review [100]). The first three fragments in real receptors are on the α-subunits and form
the main (principal) binding surface, while the last three are on non-α-subunits and compose
the complementary binding surface. In the case of homopentameric receptors like α7 ones, the
A-C loops are on the “front surface” of one α7-subunit and D-F on the “back surface“ of the
neighboring identical subunit. In general, the X-ray structure of the AChBP complex with α-
cobratoxin is in accord with the earlier ideas on the α-neurotoxin binding to nAChRs formu‐
lated on the basis of chemical modification of α-neurotoxins, their mutagenesis, photoaffinity
labeling and mutagenesis of receptors (see reviews [101,102]). Indeed, there is a multipoint
binding of α-cobratoxin and the major role, as earlier shown by “wet biochemistry” methods,
is played by the toxin central loop II.
The comparison with the NMR and X-ray structures for α-neurotoxins revealed that α-
cobratoxin did not need to change its conformation dramatically to be accommodated in the
binding region of AChBP. On the contrary, the AChBP loop C containing the disulfide between
the neighboring cysteines (which is also a characteristic feature of all nAChR α-subunits) had
to move to periphery up to 10 Å from the position which it occupied in the AChBP containing
no bound ligand. (This movement should be supplemented with essential changes in confor‐
mation of loop F from complementary AChBP protomer.) Moreover, the earlier solved
structure of AChBP with such agonist as nicotine revealed that, when agonist comes to the
binding site, loop C embraces it and moves closer to the central axis of the molecule [94]. At
present there are many crystal structures of various AChBPs in complexes with versatile
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specific or nonselective agonists and antagonists of the muscle-type and neuronal nAChRs
and it appears to be a general rule: antagonists versus agonists induce movements of the loop
C in the opposite directions.
5.1. X-ray structure of the extracellular domain of muscle nAChR α1 subunit in complex
with α-bungarotoxin
Until now we were considering the X-ray and Electron microscopy structures of closely related
but independent objects of studies: acetylcholine binding proteins and Torpedo nAChR. It
should be emphasized that the structures of bound cholinergic agonists and antagonists until
recently were available only for their complexes with AChBPs. That is why when researchers
wished to analyze in three-dimensions the interactions of agonists or antagonists with the
muscle-type or neuronal nAChRs, they had to rely on computer modeling. Fortunately, one
of the bridges between the AChBPs and nAChRs spatial structures has been recently open: the
X-ray structure has been determined for the α-bungarotoxin complex with heterologously
expressed ligand-binding domain of mouse muscle nAChR α1 subunit [25]. Many laboratories
have earlier tried, with the aid of heterologous expression, to obtain ligand-binding domains
of α1 or α7 subunits as individual proteins and to determine their three-dimensional structure.
Although in certain cases those proteins could bind α-bungarotoxin with relatively high
affinity (but not with the nanomolar constants as intact receptors) [103-106], in no case the
proteins could be crystallized. In view of the above-said, the work [25] is clearly a break‐
through. Using random mutagenesis, the authors have chosen a protein with a low tendency
to aggregation. In spite of its having the mutation of Trp149 (localized in loop B and known
to be important for binding agonists and antagonists), the protein could bind α-bungarotoxin.
It was namely the complex of α-bungarotoxin rather than the free domain which was success‐
fully crystallized. (Thus, in addition to helping isolate the Torpedo nAChR and L.stagnalis
AChBP, α-neurotoxins played again an important role, this time in crystallization of the
nAChR subunit ligand-binding domain.) The structure of the complex has been solved at a
very high resolution (1.94 Å) (see Figure 3, B).
Although this domain is a monomer, its spatial structure is very similar to an AChBP protomer
in a pentameric complex. A molecule of bound α-bungarotoxin occupies the position similar
to that of α-cobratoxin in complex with L. stagnalis AChBP (compare Figure 3, A and B). It
should be emphasized that in the complex with α1 domain, α-bungarotoxin utilized for
interaction only the principal side, while α-cobratoxin in complex with pentameric AChBP has
contacts with both principal and complementary sides at the subunit interface. However,
instead of this, α-bungarotoxin forms contacts with the sugar moiety present in the nAChR
domain but absent in AChBPs.
5.2. X-ray structure of α-bungarotoxin with a chimera of L. stagnalis AChBP/ligand-binding
domain of the human α7 subunit
This work can be considered as a further development of the recent breakthrough in the
analysis  of  ligand  binding  domains  of  nAChRs  when  an  important  step  was  done  in
ascending from models to true receptors. The authors of [107] managed to substitute about
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70% of the amino-acid residues in L. stagnalisAChBP (not touching the less hydrophobic
Cys-loop) for residues of the α7 subunit and crystallized this protein in free form and in
complex with epibatidine, an potent but nonselective nAChR agonist[108].  The observed
pentaoligomeric  structure  can be considered as  the closest  proximation to  the 3D struc‐
ture of the ligand-binding domain of the true α7 nAChR. Practically the same α7/AChBP
chimera has been used to crystallize a complex with α-bungarotoxin [26]. Again, it was a
pentaoligomer  with  5  attached  α-bungarotoxin  molecules  (see  Figure  3,  C).  In  general,
disposition of α-bungarotoxin is very close to what was observed for α-bungarotoxin in
complex  with  the  α1  domain  or  for  α-cobratoxin  complex  with  the  L.  stagnalis  AChBP
(compare with Figure 3, B and A). Basing on the high-resolution structure of the α7/AChBP-
α-bungarotoxin chimera, the authors designed a series of α7 nAChR mutants and from the
analysis of their activities and efficiency of α-bungarotoxin binding collected a very detailed
information  about  the  intermolecular  interactions  which  ensure  the  high  affinity  for  α-
bungarotoxin binding [26]. In particular, they not only confirmed the role of the “aromat‐
ic box”, but also revealed the importance of amino-acid residues which in the amino acid
sequence are direct neighbors of those aromatic residues.
5.3. X-ray structure structures of AChBP complexes with α-conotoxins
The first X-ray structure of the AChBP complex with α-conotoxin [109] has been solved soon
after elucidation of the X-ray structure of the L. stagnalis AChBP complex with α-cobratoxin.
Figure 3. Crystal structures of the AChBP/nAChR domain-toxin complexes. Top and side views are in upper and lower
lines, respectively. A - α-Cobratoxin bound to L. stagnalis AChBP (PDB ID: 1YI5); toxins and proteins are shown in blue
and green. B – α-Bungarotoxin bound to the N-terminal domain of nAChR α1 subunit (2QC1); toxin and subunit are
shown in blue and red; the sugar moiety presented in this complex were excluded for clarity. C - α-Bungarotoxin
bound to the chimeric protein composed of N-terminal domain of nAChR α7 subunit and L. stagnalis AChBP (4HQP);
toxins and chimeras are shown in blue and magenta.
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In this case it was another AChBP, namely the protein from the marine mollusk Aplysia
californica [110]. First of all, contrary to the α-cobratoxin complex, it was a high-resolution (2.4
Å) structure and, secondly, it was the first X-ray structure for a representative of the huge
conotoxin library in complex with a biological target. The crystals were raised for the complex
of α-conotoxin PnIA analog having two substitutions ([A10L] and [D14K]) which had high
affinity both for L. stagnalis and A. californica AChBPs and potently inhibited acetylcholine-
induced currents in α7 nAChRs expressed in oocytes [109].
Hydrophobic contacts were found to play the major role in the interaction of α-conotoxin
PnIA[A10L, D14K] with A. californica AChBP (Figure 4, A). As in other AChBP complexes
with agonists or antagonists, at the principal side the contacts are formed mainly by highly
conserved aromatic amino acid residues - Trp145, Tyr186, Tyr193. At the complementary
side  the  contributions  are  from aliphatic  residues  (Val106,  Met114,  Ile116).  It  should be
stressed again that loop C in the complex with α-conotoxin moves to the periphery of the
AChBP molecule by more than 10 Å, as compared with its disposition in the “apo” form
of A. californica AChBP. A similar shift was also observed, as mentioned above, for the α-
cobratoxin  complex  [24],  as  well  as  for  the  majority  of  AChBP  complexes  with  other
antagonists (see reviews [98,111,112]). Thus, the conclusion that the most obvious distinc‐
tion  between the  first  steps  in  the  binding  modes  of  agonists  versus  antagonists  is  the
induced movement of the loop C (to the central axis for the former and outwards for the
latter)  appears  to  be  correct.  However,  there  are  some  deviations  from  this  trend:  for
example, strychnine is an antagonist both of the nAChRs and glycine receptors, but in the
case of its complex with the A. californica  AChBP, the loop C shift  to the periphery was
only very slight [113]. The changes in the disposition of the loop C were not pronounced
also for AChBP complexes with partial agonists [96].
Another interesting feature of AChBP complexes was for the first time observed with partial
agonists: in distinct binding sites within a pentameric AChBP molecule these compounds
Figure 4. Spatial organization of complexes of α-conotoxins from different groups and A. californica AChBP derived
from their crystal structures. Only two adjacent monomers of AChBP colored in cyan and yellow for clarity in side views
are presented. All α-conotoxins are shown in magenta. A – complex with α-conotoxin PnIA[A10L, D14K] variant from
4/7 α-conotoxin group (PDB ID: 2BR8). B – complex with α-conotoxin ImI from 4/3 α-conotoxin group (2C9T). C - com‐
plex with α-conotoxin BuIA from 4/4 α-conotoxin group (4EZ1).
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had different orientations [96]. Such multiplicity was first thought to be inherent only in
partial  agonists,  but  later  altering  dispositions  in  the  5  AChBP  binding  sites  were  ob‐
served for  the  complexes  of  such alkaloid antagonists  as  strychnine and d-tubocurarine
[113]. Moreover, in several binding sites two alkaloid molecules managed to be accommo‐
dated simultaneously [113].
Variations of the ligand orientation in the binding sites of AChBPs and nAChRs are of
undoubted interest. In the A. californica AChBP complex, all 5 bound α-conotoxin PnIA[A10L,
D14K] molecules had the same conformation and orientation. This was also true for the later
solved structures of α-conotoxin ImI complexes [114,115] (see Figure 4, B). These structures
(very similar to those of α-conotoxin PnIA[A10L, D14K]) confirmed that, although bound α-
conotoxin PnIA analog had two substitutions and was in this respect “unnatural α-conotoxin”,
the X-ray structure of its complex correctly revealed the structural principles of the α-cono‐
toxin-AChBP recognition. Fine adjustments of such a recognition were brought to light by the
structure of A. californica AChBP complex with the α-conotoxin TxIA[A10L] [116]. In general,
the structure of this complex was very similar to those of α-conotoxin PnIA[A10L, D14K] or
α-conotoxin ImI, but with a noticeable difference: this α-conotoxin derivative occupied exactly
the same region as the two above-mentioned α-conotoxins, but it was turned around the central
axis by about 20 degrees. The authors proposed that such rotation reflects certain differences
in the selectivity of this particular α-conotoxin [116]. The latest published structure of the
AChBP complex with α-conotoxin (November 2013) is announced by the Protein Data Bank
(PDB) the structure with ID - 4EZ1. This is a complex of A. californica AChBP with α-conotoxin
BuIA [117]. Despite the fact that α-conotoxin BuIA is a member of other subgroup of α-
conotoxins (4/4) its position and orientation in the complex with AChBP (Figure 4, C) very
close to that of both α-conotoxin PnIA analog (4/7 subgroup) and α-conotoxin ImI (4/3
subgroup) (compare Figure 4, A, B and C). In any case, from the four solved X-ray structures
for AChBP complexes with α-conotoxins it followed that some variations in their attachment
are possible. It might be expected that variations may be even more pronounced when α-
conotoxins interact with true nAChRs, especially with heteroligomeric ones having different
subunit interfaces.
Indeed, interpretation of the cross-linking of photoactivatable derivative of α-conotoxin GI to
Torpedo californica nAChR in terms of the model built on the basis of the X-ray structure of the
AChBP complex with α-conotoxin PnIA[A10L, D14K], suggested that for bound α-conotoxin
two orientations are possible where the disposition of photoactivatable group differs by about
90 degrees [118]. Later a similar situation was demonstrated for an agonist, namely for the
photoactivatable derivative of epibatidine [119]. This compound was shown to bind to only
one site in the T. californica nAChR, but to 2 sites in the neuronal α4β2 nAChR which presumes
two different dispositions of the bound ligand [119]. Naturally, cross-linking is not such a direct
evidence as the X-ray structure, but the latter are available only for the AChBP complexes and
the multiplicity of alkaloid antagonist orientations in the frames of one AChBP molecule [113]
has been already mentioned.
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6. Summary
In this chapter we tried to briefly present almost a 50-year history of using protein and peptide
neurotoxins in fundamental and practical studies of nicotinic acetylcholine receptors
(nAChRs). It was shown that the discovery of α-neurotoxins in the snake venoms was an
extremely important step which made possible identification and isolation in individual form
of the first nAChR from the Torpedo ray electric organ. Many laboratories comprehensively
analyzed this receptor and it soon became clear that it is an appropriate model for nAChRs of
all classes, namely muscle, neuronal and the so-called “non-neuronal” ones. Later, in addition
to the three-finger α-neurotoxins, new shorter and smaller but not less efficient tools were
found: namely, among a huge family of various peptides in the venoms of marine Conus
mollusks, one particular group happened to be invaluable for research on nAChRs. Here we
speak about α-conotoxins which not only discriminate the muscle-type from neuronal
nAChRs, but some of them even are selective towards a particular neuronal nAChR subtype.
One should not think that the discovery of α-conotoxins put the α-neurotoxins into archives.
First of all, even to-day α-bungarotoxin and its radioactive and fluorescent derivatives are the
most reliable tools for identification and measuring the levels of the functional α7 nAChRs.
Secondly, α-neurotoxins played another leading role a decade ago helping to purify the
acetylcholine-binding protein (AChBP). The discovery and the X-ray structure of this protein,
an ideal model for the ligand-binding domains of all nAChRs, was the major breakthrough in
elucidating the three-dimensional structure of nAChRs and especially of their ligand-binding
site topography. Our chapter also presented the data on the crystal structures of AChBP
complexes both with α-neurotoxins and α-conotoxins that gave information about the
topography of their interactions with the key residues in the binding site, thus providing a
basis for new drug design. The next step was the establishment of the crystal structures of α-
neurotoxins with chimera of AChBP and α7 nAChR ligand-binding domain, which can be
considered as a good mimic of the true α7 receptor, as well as the X-ray structure of the α-
bungarotoxin complex with a mutated nAChR α1 subunit extracellular domain. In this chapter
we were not discussing the bacterial pentameric ligand-gated ion channels (belonging to the
same family as nAChRs), but at present not only high-resolution X-ray structures are available
for them, but also for their complexes with different ligands. In particular, one of such receptors
(ELIC) happened to be a close analog of the mammalian GABA-A receptors. We might hope
that one day high resolution structures become available for nAChRs or their homologs in
complexes with α-neurotoxins and/or α-conotoxins, to which the chapter is devoted. It will
give new life to these still invaluable tools in fundamental research on nAChRs and in
numerous practical applications.
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